The SGENE samples (samples from six European groups, http://www.sgene.eu/) typed on the HumanHap300 chip were used in phase I of the study (Table 1). In phase II, (Table 2) CNV data were derived from the HumanHap300 chip, the HumanHap550 chip, the Affymetrix GeneChip(r) GenomeWide SNP 6.0 or dosage measured using Taqman probes27. The Scottish samples in Table 2 were typed at Duke University (HumanHap550) in collaboration with GlaxoSmithKline as were 420 of the German samples, all from Munich (HumanHap300). The remaining CNV data (HumanHap550) from Germany (Table 2, n=491) were obtained from the University of Bonn. Norwegian samples (Affymetrix GeneChip(r) GenomeWide SNP 6.0 array) were analysed using the Affymetrix Power Tools 1.8.0. Dosage data for Danish and Chinese samples were generated at deCODE using Taqman assays27. Samples with CNVs were verified by genotyping respective samples using the HumanCNV370 chip.
